VISEN PHARMA-B(02561.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
VISEN PHARMA-B
02561.HK
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare.
1.330 T
02561.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    VISEN Pharmaceuticals' (HKG:2561) largest shareholders are public companies who were rewarded as market cap surged HK$412m last week

    VISEN Pharmaceuticals (HKG:2561) has seen significant control by public companies, which own 75% of the company, following a market cap surge of HK$412m last week. The largest shareholder, Ascendis Pharma A/S, holds 39% of shares, while Vivo Capital, LLC and An-bang Lu own 35% and 5.2%, respectively. The general public holds a 20% stake, and private equity firms own 35%. The lack of institutional ownership raises questions about investor confidence, but insider ownership indicates some alignment with company leadership.

    Simplywall·
    US
    ASND
    +2.95%
    HK
    02561
    +8.52%
    Simplywall·
    US
    ASND
    +2.95%
    HK
    02561
    +8.52%

    Understanding the Market | VISEN PHARMA-B rose over 4% as Parathyroid Hormone completed its first prescription in Boao recently

    VISEN PHARMA-B's stock price rose by more than 4%, with an increase of 4.68% as of the time of publication, reported at HKD 39.8. Recently, the first prescription of Parathyroid Hormone was completed in Boao. This drug has been approved in Europe and the United States and is the world's first parathyroid hormone replacement therapy. The company's CEO stated that this move is an important step in innovation in the endocrine field and will accelerate the process of obtaining domestic approval for the drug and promote product commercialization in collaboration with partners

    Zhitong·
    HK
    02561
    +8.52%
    Zhitong·
    HK
    02561
    +8.52%

    VISEN PHARMA-B: Lu Ying has been appointed as Chief Financial Officer

    According to the Zhitong Finance APP, VISEN PHARMA-B announced that Lu Ying has been appointed as the Chief Financial Officer of the company, effective from October 13, 2025

    Zhitong·
    HK
    02561
    +8.52%
    Zhitong·
    HK
    02561
    +8.52%

    Understanding the Market | VISEN PHARMA-B rises nearly 4% again, Longpei Growth Promoter is expected to be approved for listing within the year, and the company continues to advance its commercialization process

    VISEN PHARMA-B rose nearly 4% again, as of the time of writing, up 2.81%, priced at HKD 44.68. According to VISEN PHARMA's prospectus, the company's fastest research and development progress is in Longpei Growth Hormone (long-acting growth hormone), which is expected to be approved for domestic listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be listed in China. Currently, the company has two unique products, namely Nepeptin and Parotipratide, with the latter expected to submit a listing application by the end of 2025. It is reported that in June this year, VISEN PHARMA reached a cooperation agreement with WuXi Biologics to promote localized production, striving to meet the clinical needs of domestic patients with cost-effective high-value products. In July this year, VISEN also partnered with Anke Bio to jointly promote the commercialization of products, and the future market prospects are worth looking forward to

    Zhitong·
    HK
    02561
    +8.52%
    Zhitong·
    HK
    02561
    +8.52%

    "Performance" VISEN PHARMA's half-year loss expands to 118 million RMB, no dividend declared

    VISEN PHARMA-B announced its interim results for the period ending June this year, with other income of RMB 5.301 million, a year-on-year decrease of 26.9%. Losses widened to RMB 118 million, compared to a loss of RMB 83.471 million in the same period last year; loss per share is RMB 1.18. No dividend is declared

    AASTOCKS·
    HK
    02561
    +8.52%
    AASTOCKS·
    HK
    02561
    +8.52%
    © 2026 Longbridge｜Disclaimer